National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Anaphylaxis is not the name you expected.
Anaphylaxis is a rare, generalized, potentially life-threatening allergic reaction to a particular substance (allergen) to which individuals have previously developed an extreme sensitivity (hypersensitivity). The reaction typically occurs within seconds or minutes or, more rarely, up to a few hours after exposure to such an allergen. Allergens may include insect venom, certain foods, medications, vaccines, chemicals, or other substances. An anaphylactic reaction may be characterized by development of an itchy, reddish rash (hives); a severe drop in blood pressure; swelling and obstruction of the mouth, nose, and throat; abdominal cramps; nausea and vomiting; diarrhea; and severe difficulties breathing. Without immediate, appropriate treatment, the condition may rapidly lead to a state of unconsciousness (coma) and life-threatening complications.
During an anaphylactic reaction, entry of the allergen into the bloodstream triggers the release of large amounts of the chemical histamine and other chemicals from certain cells (e.g., mast cells, basophils). The release of these substances leads to widening (dilation) of blood vessels; an associated, severe drop in blood pressure; and leakage of fluid through blood vessel walls into surrounding tissues. As a result, affected individuals may develop itchy (pruritic), raised white areas on the skin surrounded by reddish inflammation (hives or urticaria); swelling; and stinging or prickling sensations of the skin.
The digestive (gastrointestinal) tract may also be affected, resulting in nausea, vomiting, abdominal cramping, or diarrhea. Excessive release of histamine may also cause severe narrowing (constriction) of the lung's airways (bronchi), resulting in tightness of the chest, coughing, a high-pitched whistling sound while breathing (wheezing), and shortness of breath (dyspnea). There may also be swelling and associated obstruction of the nose, mouth, tongue, and throat, potentially obstructing the air supply and causing severe difficulties breathing (respiratory distress). Some affected individuals may also develop cardiovascular symptoms such as abnormal heart rhythms (arrhythmias). In addition, a severe drop in blood pressure may lead to an extreme reduction of blood flow throughout the body (shock), leading to lost consciousness (coma) and potentially life-threatening complications.
Anaphylaxis is caused by an excessive immune response (hypersensitivity) upon exposure to a previously encountered foreign substance (allergen). Affected individuals produce certain proteins known as antibodies (i.e., immunoglobulin E [IgE]) that recognize particular allergens as foreign. When an allergen enters the bloodstream, such antibodies are secreted into the blood and react with the foreign proteins, causing certain cells (e.g., basophils, mast cells) to release histamine and other chemicals (chemical mediators) involved in inflammatory responses. The release of these chemicals may result in constriction of the lung's airways (bronchi), widening (dilation) of blood vessels, and leakage of fluid through blood vessel walls, leading to the symptoms and findings associated with an anaphylactic reaction.
Anaphylaxis may result from injection, inhalation, or swallowing of, or skin exposure to an allergen to which an individual has an extreme, previously developed sensitivity. "Injected" allergens may include insect venom, particularly from wasps, bees, hornets, or fire ants, or injected foreign proteins that are therapeutic agents. These may include vaccines, insulin, certain muscle relaxants, or extracts of the proteins of certain allergens (allergenic extracts) that may be used in the diagnosis or treatment (desensitization therapy) of allergies. Certain medications may provoke a reaction through injection as well as through ingestion, such as certain antibiotics, particularly penicillin. In individuals with extreme sensitivity to latex, an anaphylactic reaction may result from skin exposure to, or inhalation of, particles from latex products. Anaphylaxis due to severe food allergies usually results from consumption of (rather than skin contact with) allergens. Foods that most commonly trigger an anaphylactic reaction include shellfish, nuts, chocolate, eggs, and milk. In rare cases, certain fruits and vegetables such as kiwi or celery have caused anaphylaxis.
According to reports in the medical literature, exercise may also induce anaphylaxis in some cases. In addition, some individuals may develop an anaphylactic reaction when they ingest a particular food and then engage in exercise - yet do not develop a reaction if they perform either activity alone. These cases may be referred to as exercise-induced food anaphylaxis.
In some instances, the specific allergen responsible for triggering an anaphylactic reaction remains unknown (idiopathic anaphylaxis).
Anaphylaxis appears to affect males and females of all age groups in equal numbers. Anaphylaxis is considered a rare disorder, but some researchers believe it may be underdiagnosed, making it difficult to determine its true frequency in the general population.
Some of the symptoms of the following condition may be similar to those seen in anaphylaxis. Comparisons may be useful for a differential diagnosis:
Anaphylactoid reactions are "anaphylactic-like" episodes in which similar symptoms and findings result due to an initial exposure to a particular substance. In other words, the reaction does not result from allergy or previous sensitization to the substance in question. Anaphylactoid reactions have been associated with injections of certain medications, including opioids or pentamidine, or injection of contrast medium during specialized x-ray evaluations. (A contrast medium is a substance that is opaque to x-rays and therefore improves the imaging of internal organs that may otherwise be difficult to visualize.)
In individuals who are experiencing anaphylaxis, immediate treatment with epinephrine is essential. Epinephrine is a naturally occurring hormone that is secreted by the adrenal glands in response to impulses from the sympathetic nervous system, a part of the nervous system responsible for controlling involuntary functioning during times of stress. Release of the hormone serves to widen (dilate) the lung's airways, narrow (constrict) blood vessels, and increase the heart rate. Although such therapy is usually effective in arresting an anaphylactic reaction, the episode must be treated as an emergency, requiring immediate medical assistance, thorough evaluation of respiratory and cardiovascular functioning, and additional treatment as required. Additional therapeutic measures may include administration of antihistamine and corticosteroid medications, infusion of fluids into the bloodstream via a vein (intravenous infusion), and oxygen therapy.
Individuals who have previously experienced severe reactions to insect stings or certain foods, medications, or other substances should avoid exposure to the allergen in question if possible. In addition, they should always carry a preloaded syringe of epinephrine for prompt self-treatment or, if incapacitated, for immediate administration by others who have been educated in the proper method of injection.
Some affected individuals may respond to immunotherapy (desensitization therapy), during which gradually increasing doses of purified extracts of the allergen are injected into the skin. The purpose of immunotherapy is to decrease the sensitivity of the immune system to the allergen. However, such therapy carries a risk of causing anaphylaxis and therefore should only be performed with great caution and in a proper medical setting with necessary emergency medications available.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Hypersensitivity disorders. In: Beers MH, et al., eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:1053-1054.
Austen KF. Diseases of immediate type hypersensitivity. In: Fauci, AS, et al., eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill, Inc.; 1998:1862-1864.
Shimamoto SR, Bock SA. Update on the clinical features of food-induced anaphylaxis. Curr Opin Allergy Clin Immunol. 2002;2:211-16.
Rusznak C, Peebles RS Jr. Anaphylaxis and anaphylactoid reactions. A guide to prevention, recognition, and emergent treatment. Postgrad Med. 2002;111:101-4, 107-8; 111-14.
Ogawa R. Distributive shock and its therapy by cardio-vascular acting drugs. Nippon Geka Gakkai Zasshi. 1999;100:679-682.
Patterson R, et al. Idiopathic anaphylaxis. Allergy Asthma Proc. 1999;20:311-315.
Kimyai-Asadi A, et al. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry. 1999;60:714-725.
Fisher MM, et al. Failure to prevent an anaphylactic reaction to a second neuromuscular blocking drug during anaesthesia. Br J Anaesth. 1999;82:770-773.
Johnson JR, et al. Life-threatening reaction to vancomycin given for noninfectious fever. Ann Pharmacother. 1999;33:1043-1045.
Nendick M. Anaphylactic reactions during chemotherapy. Prof Nurse. 1999;14:553-556.
Schonwald S. Methylprednisolone anaphylaxis. Am J Emerg Med. 1999;17:583-585.
Ponvert C, et al. Allergy to beta-lactam antibiotics in children. Pediatrics. 1999;104:e45.
American Academy of Allergy, Asthma and Immunology
- 611 East Wells Street
- Milwaukee, WI 53202
- Tel: (414)272-6071
- Fax: (414)276-3349
- Tel: (800)822-2762
- Email: firstname.lastname@example.org
- Website: //www.aaaai.org
Asthma and Allergy Foundation of America, Inc.
- 8201 Corporate Drive
- Suite 1000
- Landover, MD 20785
- Tel: (202)466-7643
- Tel: (800)727-8462
- Email: email@example.com
- Website: //www.aafa.org
Genetic and Rare Diseases (GARD) Information Center
- PO Box 8126
- Gaithersburg, MD 20898-8126
- Tel: (301)251-4925
- Fax: (301)251-4911
- Tel: (888)205-2311
- Website: //rarediseases.info.nih.gov/GARD/
NIH/National Institute of Allergy and Infectious Diseases
- NIAID Office of Communications and Government Relations
- 5601 Fishers Lane, MSC 9806
- Bethesda, MD 20892-9806
- Tel: (301)496-5717
- Fax: (301)402-3573
- Tel: (866)284-4107
- Email: firstname.lastname@example.org
- Website: //www.niaid.nih.gov/
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
For additional information and assistance about rare disorders, please visit the National Organization for Rare Disorders web site at www.rarediseases.org
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report.
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
Last Updated: 4/4/2008
Copyright 2003 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.